Senior Vice President, Chief Commercial Officer · Akebia Therapeutics, Inc. (AKBA)

Dell Faulkingham

A named executive officer of Akebia Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,267,970

Salary $477,090Stock awards $214,520Bonus $75,000

FY2020: $1,759,476

4th of 6 named executive officers at Akebia Therapeutics by FY2021 total.

6 named officers on file for Akebia Therapeutics, FY2021

Dell Faulkingham’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 7 equity grants, each cited to its filing
  • AKBA’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Akebia Therapeutics’s whole pay program stands against its peers

  • Akebia Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AKBA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A).

Free

Get Dell Faulkingham’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Dell Faulkingham compensation by year

Akebia Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Akebia Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021
Salary$297,692$464,770$477,090
Bonus$0$0$75,000
Stock awards$111,250$569,028$214,520
Option awards$663,560$530,404$259,266
Non-equity incentive$169,200$185,250$234,551
Pension and deferred compensation$0$0—
All other$0$10,025$11,238
Total$1,241,702$1,759,476$1,267,970

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Akebia Therapeutics, Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-125281, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Akebia Therapeutics, Inc. filed document, accession 0001193125-22-125281. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

$1.2M
$1.8M
$1.3M
FY19
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU98,667$222,987—
Option110,000—$3.46
Option52,875—$8.87
Option93,750—$4.45
Option32,502—$0.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Akebia Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Akebia Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
John ButlerPresident and Chief Executive Officer$3,133,316
David SpellmanSenior Vice President, Chief Financial Officer and Treasurer$1,721,477
Steven BurkeSenior Vice President, Chief Medical Officer$1,346,572
Dell Faulkingham · this pageSenior Vice President, Chief Commercial Officer$1,267,970
Michel DahanSenior Vice President, Chief Operating Officer$1,267,970
Nicole HadasSenior Vice President, Chief Legal Officer$1,230,453

The full Akebia Therapeutics compensation record

free company brief

This page is one person within Akebia Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Akebia Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Akebia Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Dell Faulkingham's compensation dossier · One-time report. No refunds.